Page last updated: 2024-12-05

dromostanolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dromostanolone: synthetic anabolic androgenic steroid used to lower plasma cholesterol & as antineoplastic agent in advanced breast neoplasms; major descriptor (66-86); on-line search ANDROSTANOLS (80-86); ANDROSTANES (68-86); INDEX MEDICUS search DROMOSTANOLONE (66-86); RN given refers to (2alpha,5alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6011
CHEMBL ID1582
CHEBI ID34838
SCHEMBL ID19561
MeSH IDM0263246

Synonyms (55)

Synonym
hsdb 3319
drostanolo [dcit]
5alpha-androstan-3-one, 17beta-hydroxy-2alpha-methyl-
ccris 2777
5-alpha-androstan-3-one, 17-beta-hydroxy-2-alpha-methyl-
drostanolonum [inn-latin]
17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one
androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-
androstan-3-one, 17-hydroxy-2-methyl-, (2-alpha,5-alpha,17-beta)-
einecs 200-367-9
drostanolone [inn:ban]
2-alpha-methyldihydrotestosterone
drostanolona [inn-spanish]
testosterone, 4,5alpha-dihydro-2alpha-methyl-
ai3-52812
2-alpha-methyl-17-beta-hydroxy-5-alpha-androstan-3-one
dihydro-2-alpha-methyltestosterone
metholone
drostanolone
medrotestron
dihydro-2.alpha.-methyltestosterone
nsc26198
2.alpha.-methyldihydrotestosterone
ski 27719
dromostanolone
5.alpha.-androstan-3-one, 17.beta.-hydroxy-2.alpha.-methyl-
58-19-5
testosterone,5.alpha.-dihydro-2.alpha.-methyl-
methalone
(2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one
drostanolonum
drostanolona
CHEBI:34838 ,
17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one
DB00858
dihydro-2alpha-methyltestosterone
2alpha-methyldihydrotestosterone
medrosteron
CHEMBL1582
(2r,5s,8r,9s,10s,13s,14s,17s)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
drostanolo
7dr7h00hdt ,
unii-7dr7h00hdt
SCHEMBL19561
drostanolone [hsdb]
drostanolone [inn]
(2.alpha.,5.alpha.,17.beta.)-17-hydroxy-2-methylandrostan-3-one
dromostanolone [mi]
drostanolone [who-dd]
androstan-3-one, 17-hydroxy-2-methyl-, (2.alpha.,5.alpha.,17.beta.)-
DTXSID6022971
(1s,2s,4r,7s,10r,11s,14s,15s)-14-hydroxy-2,4,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one
Q422343
2|a-methyl-17|a-hydroxy-5|a-androstan-3-one
TQP0581

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This hormonal therapy should be suggested, where is possible, by the results of hormonal dosage on plasma and urine."( [Treatment of breast cancer in aged women].
Beani, G; Berta, V; Perelli-Ercolini, M, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anabolic agentA compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
anabolic androgenic steroidA steroid hormone related to the hormone testosterone. It increases protein synthesis within cells, which results in the buildup of cellular tissue (anabolism), especially in muscles. It also has androgenic and virilizing properties.
3-oxo-5alpha-steroidA 3-oxo steroid that has alpha configuration at position 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID404837Anabolic activity in rat assessed as inverse logarithm of amount of increase in levator ani muscle weight2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404838Androgenic activity in rat assessed as inverse logarithm of amount of enlargement of ventral prostate2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404839Androgenic activity in rat assessed as inverse logarithm of amount of enlargement of seminal vesicle2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404841Lipophilicity, log P of the compound2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID404840Ratio of anabolic activity in rat levator ani muscle to androgenic activity in rat seminal vesicle2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (39.13)18.7374
1990's2 (8.70)18.2507
2000's6 (26.09)29.6817
2010's4 (17.39)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.80 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index95.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]